Latest gout Stories
WASHINGTON, April 12, 2011 /PRNewswire/ -- Tart cherries have a unique combination of powerful antioxidants that may help reduce risk factors for heart disease, according to new research presented at the Experimental Biology annual meeting in Washington, DC. In a series of three studies, researchers from University of Michigan, University of Arizona and Brunswick labs studied the antioxidant levels and anti-inflammatory benefits of tart cherries.
SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling.
SAN DIEGO, March 11, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints.
TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.
Gout was known was a manâ€™s disease until a recent medical study told another story. Whatâ€™s happening to alter the pain condition equation? Medical science, leading edge technology and natural pain relief ingredients have found common ground in treating localized pain conditions.
A new topical formula for treatment of pain flares and chronic pain conditions is now available direct from the manufacturer.
The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide.
SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.